Anti-IgE (omalizumab) in the treatment of allergic rhinitis;Anti-IgE (omalizumab) en el tratamiento de la rinitis alérgica

Alergologia e Inmunologia Clinica

Volumn 19, Issue 4, 2004, Pages 133-139

  Felix Toledo R ^a   Martinez Lopez R ^a   Negro Alvarez J M ^a,b,c   Ramirez Hernandez M ^a   Merida Fernandez C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c NONE   (Spain)

Author keywords

Allergy; Anti IgE; Omalizumab; Rhinitis; RhuMAb E25

Indexed keywords

IMMUNOGLOBULIN E RECEPTOR; MONOCLONAL ANTIBODY; OMALIZUMAB;

ALLERGIC RHINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEASONAL VARIATION; SIDE EFFECT;

EID: 3542996886     PISSN: 1575734X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Corominas M. Tratamiento de las enfermedades alérgicas con anticuerpos monoclonales anti-IgE. Alergol Inmunol Clin 2001; 16: 39-45.
2. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108: S65-71.
3. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2.623-2.632.
4. Presta LG, Shields R, O'Conell L, Lahr SJ, Porter J, Gorman C, et al. The binding site on human immunoglobulin IgE for its high affinity receptor. J Biol Chem 1994; 269: 26.368-26.373.
5. Easthope S, Jarvis B. Omalizumab. Drugs 2001; 61: 253-260.
6. Schoenhoff M, Lin Y, Froelich J, Fick R, Bates D. A pharmacodynamic model describing free IgE concentrations following administration of a recombinant humanized monoclonal anti-IgE antibody in humans. Pharmacol Res 1995; 12: S411.
7. Félix Toledo R, Negro Álvarez JM, Miralles López JC. Omalizumab. Review on the new treatment of allergic asthma and seasonal allergic rhinitis. Allergol Inmunopathol 2002; 30: 2: 94-99.
8. Félix Toledo R, Negro Álvarez JM. Anti-IgE (Omalizumab): una esperanza en el tratamiento de las enfermedades alérgicas. Rev Clin Esp 2003; 203: 196-198.
9. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-121.
10. Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83.
11. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2.956-2.967.
12. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-259.
13. Plewaco H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, et al. The effect of Omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110: 68-71.
14. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280.
15. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 111: 428-430.
16. Feuchtinger T, Bartz H, von Berg A, Riedinger F, Brauburger J, Stenglein S, et al. Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J Allergy Clin Immunol 2003; 110: 728-735.
17. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91: 160-167.
18. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.